Lonza | LONN - Sales Revenues

Stock Price
485.70
Daily Change
-2.30 -0.47%
Monthly
-4.95%
Yearly
-13.97%
Q2 Forecast
460.06

Lonza reported CHF3.58B in Sales Revenues for its fiscal semester ending in June of 2025.





Sales Change Date
Akzo Nobel EUR 2.39B 20M Mar/2026
Alcon AG USD 2.69B 10M Mar/2026
Almirall EUR 547.63M 12.83M Dec/2025
AstraZeneca USD 15.29B 213M Mar/2026
BASF EUR 16.02B 1.99B Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Beiersdorf EUR 2.48B 170M Mar/2026
Covestro EUR 2.92B 255M Dec/2025
Demant DKK 6.25B 800M Dec/2025
Fresenius EUR 5.74B 140M Mar/2026
Fresenius Medical Care EUR 4.61B 460M Mar/2026
Geberit CHF 715.4M 67.1M Dec/2025
Genmab DKK 1.06B 36M Dec/2025
Givaudan CHF 3.61B 256M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
GN Store Nord DKK 3.85B 830M Mar/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Johnson Matthey GBP 1.28B 4.76B Sep/2025
Merck EUR 5.13B 120M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Philips EUR 3.91B 1.19B Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Sika AG CHF 5.52B 151.5M Dec/2025
Smith & Nephew USD 3.18B 353M Dec/2025
Solvay EUR 997M 2M Mar/2026
UCB EUR 4.25B 764M Dec/2025